NEW YORK (GenomeWeb) – Meridian Bioscience today announced an agreement with healthcare alliance Premier to offer Meridian's illumigene molecular tests.

Premier serves more than 3,000 hospitals and 110,000 other healthcare sites. Under the agreement, Premier facilities will offer Meridian's tests for C. difficile, Group A and B Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae on the illumigene platform, which uses loop-mediated isothermal DNA amplification technology to provide results in less than one hour.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.